FMP
Nanobiotix S.A.
NBTX
NASDAQ
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
3.39 USD
0.18 (5.31%)
Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
56.77k
11.35k
5.42M
41.11M
-13.18M
-13.84M
-14.53M
-15.26M
-16.02M
-16.82M
Revenue %
-
-80
47.66k
658.12
-132.06
5
5
5
5
Operating Cash Flow
-31.26M
-33.91M
-42.13M
-14.16M
-22.2M
6.49M
6.81M
7.15M
7.51M
7.89M
Operating Cash Flow %
-55.08k
-298.72k
-776.88
-34.46
168.41
-46.89
-46.89
-46.89
-46.89
Cap Ex
-121.48k
-264.53k
-105.59k
-382.61k
-962.76k
5.62M
5.9M
6.19M
6.5M
6.83M
Cap Ex %
-214
-2.33k
-1.95
-0.93
7.3
-40.58
-40.58
-40.58
-40.58
Free Cash Flow
-31.39M
-34.18M
-42.23M
-14.55M
-23.16M
12.1M
12.71M
13.35M
14.01M
14.71M
